Empagliflozin · Jardiance

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Treatment of type 2 diabetes mellitus
Product first approved 2014PMDA
EU
  • Type 2 diabetes mellitus Jardiance is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance in addition to other medicinal products for the treatment of diabetes For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. Heart failure Jardiance is indicated in adults for the treatment...
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (77)
Chronic Kidney Disease
NCT07107945 · Boehringer Ingelheim
2025-12-09 – 2028-04-14 · Chronic Kidney Disease
What this study did
NCT05715814 · University Health Network, Toronto
2024-09-01 – 2027-12-01 · Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors, Kidney Dysfunction, Residual Kidney Function
What this study did
NCT03933956 · Singapore General Hospital
2020-01-09 – 2020-08-01 · Diabetic Nephropathies
What this study did
NCT03173963 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2017-05-27 – 2020-02-21 · Diabetic Kidney Disease, Diabetes Mellitus Type 2
What this study did
Heart Failure
NCT05392764 · Juntendo University
2022-09-10 – 2027-12-31 · Acute Heart Failure
What this study did
NCT06024746 · Colorado Prevention Center
2024-07-09 – 2027-11 · Heart Failure
What this study did
NCT07038356 · Christian Schulze
2025-12-08 – 2027-06-30 · Acute Decompensated Heart Failure (ADHF)
What this study did
NCT05182658 · National Institute of Cardiology, Warsaw, Poland
2022-06-01 – 2026-11-30 · Hypertrophic Cardiomyopathy, Heart Failure
What this study did
NCT05776043 · Medical University of Warsaw
2022-03-15 – 2025-12-31 · Acute Decompensated Heart Failure
What this study did
NCT06683053 · Conrado Roberto Hoffmann Filho
2023-03-17 – 2025-02-28 · Congestive Heart Failure (CHF)
What this study did
NCT05556044 · Chinese University of Hong Kong
2022-09-27 – 2024-05-31 · Acute Heart Failure
What this study did
NCT04509674 · Boehringer Ingelheim
2020-12-16 – 2023-11-05 · Myocardial Infarction
What this study did
NCT03087773 · Medical University of Graz
2017-05-11 – 2022-05-17 · Acute Myocardial Infarction
What this study did
NCT04157751 · Boehringer Ingelheim
2020-05-18 – 2021-06-02 · Heart Failure
What this study did
NCT03332212 · Boehringer Ingelheim
2018-03-01 – 2020-05-28 · Heart Failure
What this study did
Type 2 Diabetes
NCT06083675 · Novo Nordisk A/S
2024-01-26 – 2027-05-28 · Diabetes Mellitus, Type 2
What this study did
NCT07093476 · Celltrion
2025-07-18 – 2027-04 · T2DM, Diabete Type 2, DM
What this study did
NCT06952231 · University of Lahore
2024-05-21 – 2025-01-05 · Diabetes Mellitus
What this study did
NCT05545800 · Xiangya Hospital of Central South University
2022-09-01 – 2024-06-01 · Type 2 Diabetes Mellitus
What this study did
NCT05109949 · Centro Universitario de Ciencias de la Salud, Mexico
2020-03-30 – 2022-08-01 · Diabetes Mellitus Type 2 Without Complication
What this study did
NCT04233801 · Boehringer Ingelheim
2020-04-15 – 2022-03-10 · Diabetes Mellitus, Type 2
What this study did
NCT04195243 · Centro Universitario de Ciencias de la Salud, Mexico
2019-12-02 – 2020-12-30 · Type 2 Diabetes Mellitus
What this study did
NCT03151343 · Caroline M Kistorp
2017-03-29 – 2020-05-22 · Type2 Diabetes Mellitus
What this study did
NCT03118336 · Assistance Publique Hopitaux De Marseille
2017-06-16 – 2020-02-07 · Type 2 Diabetes
What this study did
NCT02752113 · Institut für Pharmakologie und Präventive Medizin
2016-04 – 2019-05 · Diabetes Mellitus Type 2
What this study did
NCT03060980 · Intarcia Therapeutics
2017-03-03 – 2018-01-26 · Diabetes Mellitus, Type 2
What this study did
NCT02489968 · Boehringer Ingelheim
2015-05-12 – 2017-06-16 · Diabetes Mellitus, Type 2
What this study did
NCT02182830 · Boehringer Ingelheim
2014-07-25 – 2017-05-18 · Diabetes Mellitus, Type 2, Hypertension
What this study did
NCT02453555 · Boehringer Ingelheim
2015-05-14 – 2017-03-27 · Diabetes Mellitus, Type 2
What this study did
NCT01984606 · Boehringer Ingelheim
2015-01 – 2017-02 · Diabetes Mellitus, Type 2
What this study did
NCT02471963 · University of Erlangen-Nürnberg Medical School
2014-12 – 2016-06 · Diabetes Mellitus Type 2
What this study did
NCT01167881 · Boehringer Ingelheim
2010-08 – 2015-08 · Diabetes Mellitus, Type 2
What this study did
NCT01734785 · Boehringer Ingelheim
2013-02-08 – 2015-03-23 · Diabetes Mellitus, Type 2
What this study did
NCT01778049 · Boehringer Ingelheim
2013-01 – 2015-03 · Diabetes Mellitus, Type 2
What this study did
NCT01719003 · Boehringer Ingelheim
2012-10 – 2014-12 · Diabetes Mellitus, Type 2, Hyperglycemia
What this study did
NCT01947855 · Boehringer Ingelheim
2013-09 – 2013-12 · Diabetes Mellitus, Type 2
What this study did
NCT01289990 · Boehringer Ingelheim
2011-02 – 2013-05 · Diabetes Mellitus, Type 2
What this study did
NCT01368081 · Boehringer Ingelheim
2011-05 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT01164501 · Boehringer Ingelheim
2010-07 – 2012-07 · Diabetes Mellitus, Type 2, Renal Insufficiency
What this study did
NCT01370005 · Boehringer Ingelheim
2011-06 – 2012-07 · Diabetes Mellitus, Type 2, Hypertension
What this study did
NCT01210001 · Boehringer Ingelheim
2010-09 – 2012-04 · Diabetes Mellitus, Type 2
What this study did
NCT01177813 · Boehringer Ingelheim
2010-07 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
Phase 2/3 (19)
Chronic Kidney Disease
NCT07214818 · Mansoura University
2025-11-15 – 2026-09-06 · Nephrotic Syndrome
What this study did
NCT05373004 · Omar Tarek Elfarargi
2023-03 – 2024-05 · Diabetic Nephropathy Type 2
What this study did
Heart Failure
NCT05580510 · Instituto Nacional de Cardiologia Ignacio Chavez
2023-02-06 – 2024-03-29 · Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction
What this study did
Other / comorbidity
NCT07828002 · Martin Blomberg Jensen
2026-10-20 – 2029-04 · Paraffinoma, Granuloma, Foreign-Body
What this study did
NCT06715449 · University of East Anglia
2024-11-22 – 2029-03 · Embolic Stroke of Undetermined Source, Atrial Fibrillation New Onset
What this study did
NCT06506422 · University of Missouri-Columbia
2024-08-18 – 2029-02-28 · Aging, Arterial Stiffness
What this study did
NCT06030843 · Chulalongkorn University
2025-03-01 – 2026-12-31 · Empagliflozin in Cardiorenal Syndrome Type 1
What this study did
NCT06149793 · University of Minnesota
2024-01-08 – 2026-12-31 · Cystic Fibrosis-related Diabetes, Cystic Fibrosis
What this study did
NCT06469645 · University of East Anglia
2024-05-30 – 2026-07-24 · Moderate Aortic Valve Stenosis
What this study did
NCT07591077 · Ain Shams University
2024-11-20 – 2026-02-20 · Type 1 Diabetes, Nephropathy, Diabetic
What this study did
NCT06103279 · Ain Shams University
2023-11 – 2024-08 · Cancer
What this study did
NCT06140108 · SINA Health Education and Welfare Trust
2023-12-15 – 2024-06-30 · Polycystic Ovary Syndrome, Weight Gain, HbA1c
What this study did
NCT05430243 · Alexandria University
2022-04-21 – 2022-11-12 · Ascites Hepatic
What this study did
NCT04342819 · The University of The West Indies
2020-01-01 – 2021-12-31 · Platelet Dysfunction Due to Drugs
What this study did
NCT03202667 · University Hospital, Basel, Switzerland
2017-12-15 – 2021-12-06 · SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia
What this study did
NCT02874807 · University Hospital, Basel, Switzerland
2016-09-05 – 2019-01-14 · SIADH
What this study did
NCT03008551 · Hull University Teaching Hospitals NHS Trust
2017-08-18 – 2018-04-02 · Polycystic Ovary Syndrome
What this study did
NCT02729766 · University Hospital, Basel, Switzerland
2016-03 – 2016-08 · Inappropriate ADH Syndrome
What this study did
Phase 2 (77)
Atherosclerotic Cardiovascular Disease
NCT07749014 · Rehman Medical Institute - RMI
2026-09-01 – 2027-09-30 · ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI), Coronary Artery Disease
What this study did
NCT07898709 · Al-Azhar University
2027-01 – 2027-08 · No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, Coronary Artery Disease (CAD), PCI, Sodium Glucose Co-Transporter 2 Inhibitors, Empagliflozin, Dapagliflozin
What this study did
Chronic Kidney Disease
NCT07060417 · VA Office of Research and Development
2026-10-01 – 2029-09-30 · Non-diabetic Chronic Kidney Disease
What this study did
NCT07304817 · University Medical Center Groningen
2026-05-12 – 2028-02 · CKD, Cardiovascular Diseases, Heart Failure
What this study did
NCT06483074 · Chinese University of Hong Kong
2024-07-29 – 2027-10-31 · End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication, Sodium-glucose Cotransporter-2 Inhibitor, Residual Kidney Function
What this study did
NCT05786443 · NYU Langone Health
2024-01-31 – 2026-12-30 · End Stage Renal Disease
What this study did
NCT06926660 · Boehringer Ingelheim
2025-07-18 – 2026-08-14 · Chronic Kidney Disease
What this study did
NCT05638880 · Mostafa Bahaa
2022-12-20 – 2025-12-20 · Diabetic Nephropathies
What this study did
NCT06818305 · Jinling Hospital, China
2025-01-01 – 2025-10-01 · Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Nephrectomy, Chronic Kidney Disease(CKD)
What this study did
NCT05182840 · Boehringer Ingelheim
2022-01-11 – 2023-07-10 · Kidney Disease, Chronic
What this study did
NCT04143581 · Mario Negri Institute for Pharmacological Research
2021-09-03 – 2021-09-03 · Obesity, Non-diabetic Chronic Kidney Disease
What this study did
NCT03713190 · University of Pisa
2018-09-10 – 2020-03-15 · End Stage Renal Disease
What this study did
NCT03078101 · Medical University of Vienna
2017-04-15 – 2019-08-07 · Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
What this study did
Heart Failure
NCT06570473 · University of Alberta
2025-07-15 – 2027-06 · Pulmonary Hypertension, Right Ventricular Dysfunction, Right Heart Failure
What this study did
NCT05138575 · University of Pennsylvania
2022-01-24 – 2027-05-31 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT07372040 · Tanta University
2026-02-01 – 2027-02-01 · Acute Decompensated Heart Failure
What this study did
NCT07692256 · Ain Shams University
2025-12-01 – 2027-02-01 · Heart Failure
What this study did
NCT06012266 · Centre Hospitalier Universitaire Vaudois
2024-08 – 2025-08 · Heart Failure
What this study did
NCT07169981 · Ain Shams University
2023-07-12 – 2025-06-17 · Diabete Mellitus, Heart Failure, Remodeling, Left Ventricle
What this study did
NCT05042973 · Jacob Moller
2021-09-02 – 2025-01-23 · Obesity, Heart Failure
What this study did
NCT05084235 · Jacob Moller
2021-09-02 – 2025-01-16 · Heart Failure, Obesity
What this study did
NCT04049045 · Christian Schulze
2019-09-29 – 2021-06-29 · Acute Decompensated Heart Failure
What this study did
NCT03128528 · University of Erlangen-Nürnberg Medical School
2017-07-01 – 2020-04-30 · Chronic Heart Failure
What this study did
NCT03198585 · Morten Schou
2017-06-29 – 2020-01-17 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT03200860 · University Medical Center Groningen
2017-12-18 – 2019-09-18 · Heart Failure Acute, Heart Failure,Congestive, Heart Failure; With Decompensation
What this study did
Type 2 Diabetes
NCT05232071 · Inventiva Pharma
2022-06-29 – 2024-06-04 · NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
What this study did
NCT04702490 · Metacrine, Inc.
2020-12-15 – 2022-06 · NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2, Diabetes, Fatty Liver, Fatty Liver, Nonalcoholic, NAFLD
What this study did
NCT04535960 · University Health Network, Toronto
2019-03-14 – 2021-03-16 · Type 2 Diabetes Mellitus
What this study did
NCT03554200 · RWTH Aachen University
2018-06-11 – 2020-10-29 · Diabetes Mellitus, Type 2, Acute Heart Failure
What this study did
NCT02890745 · Henrik Enghusen Poulsen
2016-11 – 2020-01-22 · Diabetes Mellitus, Type 2
What this study did
NCT02632747 · Boehringer Ingelheim
2016-05-10 – 2019-07-02 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
What this study did
NCT03132181 · RWTH Aachen University
2017-04-24 – 2019-01-23 · Diabetes Mellitus Type 2 (T2DM)
What this study did
NCT01867307 · Boehringer Ingelheim
2013-06 – 2015-10 · Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01193218 · Boehringer Ingelheim
2010-09 – 2012-06 · Diabetes Mellitus, Type 2
What this study did
NCT00881530 · Boehringer Ingelheim
2009-03 – 2011-05 · Diabetes Mellitus, Type 2
What this study did
NCT00885118 · Boehringer Ingelheim
2009-04 – 2009-10 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07175051 · University of Illinois at Chicago
2026-04-08 – 2030-10 · Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
What this study did
NCT06992440 · Gustavo A Heresi, MD, MS
2025-06-26 – 2030-09 · Pulmonary Arterial Hypertension
What this study did
NCT06745063 · VA Office of Research and Development
2025-05-30 – 2029-12-31 · Obesity, Vascular Health
What this study did
NCT07756294 · Wake Forest University Health Sciences
2026-11 – 2028-04 · Alzheimer Disease
What this study did
NCT03867487 · Justin Ryder
2027-05-01 – 2028-02-01 · Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
What this study did
NCT06355310 · Justin Ryder
2025-04-10 – 2028-02-01 · Non-Alcoholic Fatty Liver Disease
What this study did
NCT07336797 · Abdelrahman Mahmoud
2025-09-01 – 2027-12-30 · Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)
What this study did
NCT06528405 · National Taiwan University Hospital
2024-11-21 – 2027-12 · Acute Kidney Injury
What this study did
NCT07864688 · Al-Azhar University
2026-12 – 2027-12 · Rheumatoid Arthritis (RA)
What this study did
NCT07883512 · Virginia Commonwealth University
2026-12-01 – 2027-09-30 · Breast Cancer, Supportive Care in Cancer
What this study did
NCT07146880 · National Taiwan University Hospital
2025-09-15 – 2027-09-21 · Brugada Syndrome (BrS)
What this study did
Phase 1/2 (7)
Chronic Kidney Disease
NCT05687058 · University of Mississippi Medical Center
2023-11-01 – 2026-06-20 · Kidney Failure, Chronic, Heart Failure
What this study did
Other / comorbidity
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT05972564 · Vanderbilt University Medical Center
2023-09-06 – 2027-12-30 · Obesity, Metabolic Syndrome
What this study did
NCT07947706 · Assiut University
2026-09-01 – 2027-05-01 · Empagliflozin, Hepatitis B, Steatosis
What this study did
NCT06113900 · Ain Shams University
2023-12-01 – 2025-01-30 · Lupus Nephritis
What this study did
NCT04907214 · Vanderbilt University Medical Center
2021-07-29 – 2023-12-08 · Obesity, Pre-diabetes
What this study did
NCT05977465 · Tanta University
2022-01-20 – 2023-08-03 · Diabetic Neuropathy Peripheral
What this study did
Phase 1 (93)
Atherosclerotic Cardiovascular Disease
NCT06578676 · Hyundai Pharm
2024-06-20 – 2024-11-30 · Type 2 Diabetes, Dyslipidemias
What this study did
Chronic Kidney Disease
NCT06430684 · Ann & Robert H Lurie Children's Hospital of Chicago
2024-08-23 – 2026-11-01 · Chronic Kidney Diseases, Pediatric Kidney Disease
What this study did
NCT05614115 · University of Utah
2023-03-21 – 2025-06-30 · End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic, Non-diabetic, Kidney Dysfunction, Kidney Failure, Hemodialysis
What this study did
NCT06483243 · Chong Kun Dang Pharmaceutical
2024-04-04 – 2024-05-17 · Type 2 Diabetes Mellitus
What this study did
NCT06204107 · Chong Kun Dang Pharmaceutical
2023-11-21 – 2023-12-06 · Type 2 Diabetes Mellitus
What this study did
Heart Failure
NCT06507657 · University of Minnesota
2024-12-12 – 2029-01-15 · Hypertension, Cardiovascular Diseases
What this study did
NCT05553938 · Yale University
2023-08-04 – 2026-08-14 · Heart Failure
What this study did
NCT03027960 · Yale University
2017-06-27 – 2019-06-01 · Heart Failure, Type II; Diabetes
What this study did
Type 2 Diabetes
NCT07053306 · The University of Texas Health Science Center at San Antonio
2025-04-29 – 2027-06-30 · Type 2 Diabetes
What this study did
NCT07053319 · The University of Texas Health Science Center at San Antonio
2026-05-11 – 2027-06-30 · Type 2 Diabetes
What this study did
NCT05960656 · The University of Texas Health Science Center at San Antonio
2023-10-05 – 2027-06-30 · Type 2 Diabetes
What this study did
NCT07053293 · The University of Texas Health Science Center at San Antonio
2025-01-07 – 2027-06-30 · Type 2 Diabetes
What this study did
NCT05057806 · The University of Texas Health Science Center at San Antonio
2021-01-13 – 2027-03-31 · Type2 Diabetes, Heart Failure With Preserved Ejection Fraction
What this study did
NCT06229678 · The University of Texas Health Science Center at San Antonio
2024-01-25 – 2027-03-01 · Type2diabetes, Heart Failure With Reduced Ejection Fraction
What this study did
NCT07872358 · Humanis Saglık Anonim Sirketi
2026-06-07 – 2026-10-07 · Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
What this study did
NCT07691203 · Humanis Saglık Anonim Sirketi
2026-03-07 – 2026-07-01 · Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
What this study did
NCT07694115 · Humanis Saglık Anonim Sirketi
2026-05-07 – 2026-07-01 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07372118 · Humanis Saglık Anonim Sirketi
2025-09-27 – 2026-01-07 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07266766 · Humanis Saglık Anonim Sirketi
2025-08-05 – 2025-10-06 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07213895 · Humanis Saglık Anonim Sirketi
2025-05-21 – 2025-09-18 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06932159 · Humanis Saglık Anonim Sirketi
2024-12-23 – 2025-04-08 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT04203927 · University of Virginia
2020-02-01 – 2023-11-30 · Type2 Diabetes, Insulin Sensitivity
What this study did
NCT05681273 · Chipscreen Biosciences, Ltd.
2023-02-17 – 2023-03-21 · T2DM
What this study did
NCT04869800 · Chong Kun Dang Pharmaceutical
2021-05-27 – 2021-06-15 · Type 2 Diabetes Mellitus
What this study did
NCT04431141 · Handok Inc.
2020-09-15 – 2021-01-25 · Type 2 Diabetes Mellitus
What this study did
NCT03766724 · Dong-A ST Co., Ltd.
2018-11-22 – 2019-01-18 · Type2 Diabetes
What this study did
NCT03565458 · LG Chem
2018-04-05 – 2018-12-22 · Type 2 Diabetes Mellitus
What this study did
NCT02854748 · Chong Kun Dang Pharmaceutical
2016-08 – 2016-09 · Diabetes Mellitus, Type II
What this study did
NCT02121483 · Boehringer Ingelheim
2014-06 – 2016-02 · Diabetes Mellitus, Type 2
What this study did
NCT01581658 · Boehringer Ingelheim
2012-04-01 – 2012-11-01 · Diabetes Mellitus, Type 2
What this study did
NCT01316341 · Boehringer Ingelheim
2011-03 – 2012-01 · Diabetes Mellitus, Type 2
What this study did
NCT01276288 · Boehringer Ingelheim
2011-01 – 2011-06 · Diabetes Mellitus, Type 2
What this study did
NCT01211197 · Boehringer Ingelheim
2010-10 – 2010-12 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07055282 · University of Chicago
2025-11-20 – 2028-11-01 · Kidney Stones
What this study did
NCT05360615 · Chulalongkorn University
2022-07-01 – 2027-07-01 · Empagliflozin in Post AKI Stage 2-3
What this study did
NCT06446531 · The University of Texas Health Science Center at San Antonio
2024-09-11 – 2027-07 · Pre-Diabetes, Weight, Body, Cardiovascular Diseases
What this study did
NCT07845630 · Boehringer Ingelheim
2026-10-14 – 2026-12-21 · Healthy
What this study did
NCT05610956 · Tanta University
2023-01-01 – 2026-12-01 · Ulcerative Colitis
What this study did
NCT06554301 · China National Center for Cardiovascular Diseases
2024-10-20 – 2026-12 · Pulmonary Arterial Hypertension
What this study did
NCT07331389 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-09-24 – 2026-06-13 · Overweight Subject, Healthy Subjects
What this study did
NCT06962826 · Boehringer Ingelheim
2025-05-27 – 2025-09-12 · Healthy
What this study did
NCT06828731 · Charles George VA Medical Center
2024-12-06 – 2025-09-05 · Prediabetes
What this study did
NCT07035457 · Boehringer Ingelheim
2025-07-02 – 2025-08-15 · Healthy
What this study did
NCT05078879 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-11-16 – 2025-05-21 · Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
What this study did
Phase 4 (124)
Atherosclerotic Cardiovascular Disease
NCT07292909 · Hotel Dieu de France Hospital
2025-09-01 – 2027-09-30 · CAD - Coronary Artery Disease, Inflamation, PCI, SGLT 2 Inhibitors
What this study did
NCT06280976 · University of Louisville
2024-03-01 – 2025-01-01 · Coronary Artery Disease, Atherosclerosis, Heart Attack
What this study did
NCT04117763 · University of Sao Paulo
2019-10-04 – 2024-03-31 · Diabetes Mellitus, Type 2, Coronary Heart Disease, Arrythmia, Cardiac
What this study did
NCT04523064 · University of Sao Paulo General Hospital
2020-09-22 – 2024-01-30 · Diabetes Mellitus, Type 2, Coronary Artery Disease, Coronary Artery Bypass Surgery, Acute Kidney Injury
What this study did
NCT05037695 · University of Sao Paulo General Hospital
2021-07-21 – 2022-12 · Diabetes Mellitus, Type 2, Coronary Artery Disease, Acute Kidney Injury
What this study did
NCT04497792 · Research Institute for Complex Problems of Cardiovascular Diseases, Russia
2016-11 – 2019-11 · Coronary Artery Disease, Diabetes Mellitus, Percutaneous Coronary Intervention
What this study did
NCT03208465 · CHEOL WHAN LEE, M.D., Ph.D
2017-08-07 – 2019-08-01 · Diabetes Mellitus, Coronary Disease
What this study did
Chronic Kidney Disease
NCT06249945 · National Taiwan University Hospital
2024-03-05 – 2030-12-31 · Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis
What this study did
NCT06249932 · National Taiwan University Hospital
2024-03-13 – 2030-12-31 · Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
What this study did
NCT06013865 · VA Office of Research and Development
2024-04-05 – 2030-03-31 · Kidney Transplant, Chronic Kidney Disease
What this study did
NCT07775846 · Huijie Zhang
2026-11-03 – 2029-06-30 · Type 2 Diabetic Kidney Disease
What this study did
NCT07547878 · Baylor Research Institute
2026-04-08 – 2029-03-31 · Chronic Kidney Disease, Type 2 Diabetes
What this study did
NCT06642272 · Herlev and Gentofte Hospital
2024-10-10 – 2028-12-31 · Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Diseases
What this study did
NCT06110130 · Washington D.C. Veterans Affairs Medical Center
2024-02-02 – 2028-12-01 · Chronic Kidney Diseases
What this study did
NCT07074418 · Centre Hospitalier Universitaire de Nice
2026-08-25 – 2028-05 · Chronic Kidney Diseases
What this study did
NCT07155694 · Washington D.C. Veterans Affairs Medical Center
2026-10-01 – 2027-08 · Diabetic Kidney Disease
What this study did
NCT05671991 · Yale University
2023-03-01 – 2026-12-31 · End Stage Renal Disease on Dialysis
What this study did
NCT05305495 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2022-12-22 – 2026-03-10 · Acute Heart Failure, Chronic Kidney Diseases
What this study did
NCT06094920 · University Medical Center Groningen
2024-07-29 – 2025-09-24 · Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Chronic Kidney Diseases, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, CKD, CKD Stage 3, CKD Stage 4
What this study did
NCT04243850 · Amsterdam UMC, location VUmc
2020-07-01 – 2022-03-01 · Diabetes Mellitus, Type 2, Chronic Kidney Diseases
What this study did
NCT04238702 · Amsterdam UMC, location VUmc
2020-11-04 – 2021-09-27 · Diabetes Mellitus, Type 2, Diabetic Kidney Disease
What this study did
NCT04215445 · National University of Malaysia
2019-12-01 – 2020-08 · Diabetic Retinopathy, Chronic Kidney Diseases, Diabetes Mellitus
What this study did
NCT03504566 · Steno Diabetes Center Copenhagen
2017-11-15 – 2019-06-01 · Diabetic Nephropathy Type 2
What this study did
Heart Failure
NCT06260059 · Anita Saraf
2024-09-17 – 2027-06-01 · Adult Congenital Heart Disease, Heart Failure
What this study did
NCT06055452 · China National Center for Cardiovascular Diseases
2024-01-19 – 2026-12-31 · Pre-Heart Failure, Hypertension
What this study did
NCT07926958 · Universidade do Porto
2024-03-11 – 2026-12 · Heart Failure, Acute Decompensated Heart Failure (ADHF)
What this study did
NCT05584319 · Zhijun Sun
2022-12-15 – 2025-10 · Heart Failure, Heart Failure With Preserved Ejection Fraction
What this study did
NCT05600387 · Zhijun Sun
2022-11-05 – 2025-10 · Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
What this study did
NCT06401343 · China National Center for Cardiovascular Diseases
2022-08-01 – 2025-08-01 · Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
What this study did
NCT06046612 · Maastricht University Medical Center
2023-02-13 – 2025-02-13 · Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction
What this study did
NCT05778084 · Alexandria University
2022-12-15 – 2024-12-15 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT05129722 · The George Institute
2022-10-01 – 2024-05-01 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT04583813 · Miulli General Hospital
2021-09 – 2024-04 · Atrial Fibrillation, Heart Failure, Obesity, Diabetes Mellitus
What this study did
NCT05139472 · University of Texas Southwestern Medical Center
2021-11-09 – 2024-02-19 · Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
What this study did
NCT06632561 · Ashraf Wasfy Beshay Aziz
2021-07-26 – 2022-03-14 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT03271879 · Rambam Health Care Campus
2018-02-15 – 2020-06-01 · Heart Failure, Diabetes Mellitus, Arrythmia
What this study did
NCT03485092 · NHS Greater Glasgow and Clyde
2018-03-16 – 2020-03-28 · Heart Failure, Diabetes Mellitus
What this study did
NCT03030222 · Saint Luke's Health System
2017-07-05 – 2020-03-10 · Heart Failure
What this study did
Type 2 Diabetes
NCT07771010 · University Medical Centre Ljubljana
2026-04-16 – 2028-07-31 · Diabetes Type 2
What this study did
NCT06613854 · University Medical Centre Ljubljana
2024-10-01 – 2027-12 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT05164263 · Getz Pharma
2021-04-01 – 2027-08-31 · Type II Diabetes Mellitus, Efficacy, Self, Safety Issues
What this study did
NCT07365358 · Chong Kun Dang Pharmaceutical
2026-03 – 2027-08 · Diabete Type 2
What this study did
NCT06989723 · Seoul National University Bundang Hospital
2025-01-01 – 2027-06-30 · Type 2 Diabetes, Fatty Liver
What this study did
NCT07442006 · JW Pharmaceutical
2025-10-29 – 2027-03-31 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06706791 · Fazaia Ruth Pfau Medical College
2025-04-01 – 2026-12-01 · Chronic Heart Failure
What this study did
NCT07452913 · Bahria University
2026-01-01 – 2026-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT06862739 · Nabiqasim Industries (Pvt) Ltd
2025-10-30 – 2026-06-30 · Diabetes Mellitus, Type 2 DM
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT07120828 · Erbil Polytechnic University
2025-07-15 – 2026-03-15 · Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)
What this study did
Early phase / not applicable (40)
Atherosclerotic Cardiovascular Disease
NCT04541797 · The University of Hong Kong
2020-10-01 – 2025-02-28 · Type 2 Diabetes, Microvascular Coronary Artery Disease
What this study did
NCT06313008 · Damanhour University
2023-08-10 – 2024-10-10 · Coronary Artery Disease, Type 2 Diabetes
What this study did
Chronic Kidney Disease
NCT06187493 · Assiut University
2024-01-01 – 2025-12-31 · Diabetic Kidney Disease
What this study did
NCT07866235 · Lahore General Hospital
2023-10-11 – 2024-04-10 · Diabetic Nephropathies, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
What this study did
NCT04961931 · Medical University of Lodz
2019-01-01 – 2021-08-31 · Chronic Kidney Disease stage3
What this study did
Heart Failure
NCT07112274 · Damanhour University
2022-10-01 – 2025-07-30 · Heart Failure
What this study did
NCT05967156 · Shahid Beheshti University of Medical Sciences
2023-06-01 – 2025-06-03 · Heart Failure, Hemodialysis
What this study did
NCT07556094 · Medical University of Bialystok
2023-06-05 – 2025-05-09 · Obstructive Sleep Apnea (OSA), Sleep Apnea Syndrome, Obstructive, Heart Failure
What this study did
NCT06915870 · Fatima Maqsood
2024-07-12 – 2025-01-13 · Diabetes Mellitus, Heart Failure
What this study did
NCT06065280 · Damanhour University
2022-11-01 – 2024-12-30 · Heart Failure, Reduced Ejection Fraction Heart Failure
What this study did
Type 2 Diabetes
NCT05501483 · Karolinska Institutet
2023-02-08 – 2032-12-31 · Type 2 Diabetes
What this study did
NCT06519448 · Military University Hospital, Prague
2024-04-01 – 2027-12-31 · Non-alcoholic Steatohepatitis, Liver Diseases, Diabetes Mellitus, Type 2, Fibrosis, Liver
What this study did
NCT07303556 · Nazarbayev University
2024-12-18 – 2026-11-01 · Heart Failure, Diabete Type 2, Arterial Hypertension
What this study did
NCT05313529 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2022-10-08 – 2026-07-01 · Type 2 Diabetes Mellitus, Mild Cognitive Impairment
What this study did
NCT06187285 · Medanta, The Medicity, India
2024-01-01 – 2025-06-01 · Type 2 Diabetes
What this study did
NCT05417646 · Steno Diabetes Center Copenhagen
2022-06-22 – 2023-06-14 · Maturity-Onset Diabetes of the Young, Type 3, Type 2 Diabetes
What this study did
NCT05359341 · Sadat City University
2020-09-20 – 2022-01-10 · Diabete Type 2
What this study did
NCT02792400 · University Hospital, Gentofte, Copenhagen
2016-05 – 2018-07 · Type 2 Diabetes
What this study did
NCT03771781 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2018-04-16 – 2018-05-25 · Type 2 Diabetes
What this study did
NCT02686476 · Medanta, The Medicity, India
2016-03 – 2017-12 · Non Alcoholic Fatty Liver Disease
What this study did
NCT02964572 · Yonsei University
2016-11 – 2017-07 · Type2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT07141355 · University Hospital, Strasbourg, France
2025-12-12 – 2027-09-30 · Cardiogenic Shock
What this study did
NCT07678151 · Heart Health Research Center
2026-07-13 – 2027-08-31 · Hypertension (HTN)
What this study did
NCT07472920 · University of Sao Paulo
2026-11-12 – 2027-08 · Bipolar Disorder, Bipolar Depression, Insulin Resistance
What this study did
NCT06473844 · Hospital Authority, Hong Kong
2025-03-05 – 2027-02-28 · Sepsis, Inflammation, SGLT2 Inhibitors, Critically Ill, Organ Dysfunction Syndrome
What this study did
NCT06098625 · Medanta, The Medicity, India
2023-11-10 – 2025-12-01 · Diabetes Mellitus, Kidney Transplant; Complications
What this study did
NCT06095492 · Medanta, The Medicity, India
2023-10-30 – 2025-12-01 · Kidney Transplant; Complications, Diabetes Mellitus
What this study did
NCT07633054 · ADIUM
2025-09-10 – 2025-11-24 · Bioequivalence Study in Healthy Subjects
What this study did
NCT04918407 · Shahid Beheshti University of Medical Sciences
2022-01-01 – 2025-08-05 · Kidney Transplant; Complications
What this study did
NCT07633015 · ADIUM
2025-02-17 – 2025-04-29 · Bioequivalence Study in Healthy Subjects
What this study did
NCT07633028 · ADIUM
2025-02-10 – 2025-04-08 · Bioequivalence Study in Healthy Subjects
What this study did
NCT07633041 · ADIUM
2025-02-05 – 2025-04-04 · Bioequivalence Study in Healthy Subjects
What this study did
NCT06350903 · Matthieu Pelletier-Galarneau, MD MSc
2024-06-01 – 2024-11-01 · Myocardial Suppression
What this study did
NCT05694923 · Assiut University
2023-04-01 – 2024-04-01 · Fatty Liver Disease
What this study did
NCT04520646 · Huashan Hospital
2020-09-01 – 2022-08-31 · Acromegaly, Cardiomyopathies
What this study did
NCT05229796 · Mutah University
2021-05-17 – 2021-12-12 · Pharmacokinetic Parameters
What this study did
NCT03510000 · Samuel Lunenfeld Research Institute, Mount Sinai Hospital
2018-05-15 – 2019-11-21 · Type1diabetes
What this study did
NCT03591991 · Chinese PLA General Hospital
2018-10-01 – 2019-09-01 · Reperfusion Injury, Myocardial
What this study did
NCT04061473 · University Hospital, Gentofte, Copenhagen
2019-04-02 – 2019-08-20 · Diabetes After Total Pancreatectomy
What this study did
NCT03200782 · University Hospital, Basel, Switzerland
2017-05-30 – 2018-09-21 · Postprandial Hypoglycemia, Bariatric Surgery, Late Dumping Syndrome
What this study did
Used as active comparator (21)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (10)
Atherosclerotic Cardiovascular Disease
NCT04602754 · EMS
2023-12-01 – 2027-09 · Dyslipidemia Associated With Type II Diabetes Mellitus
What this study did
NCT04603508 · EMS
2023-03 – 2025-08 · Type 2 Diabetes Mellitus, Dyslipidemia
What this study did
Heart Failure
NCT05364190 · October 6 University
2022-06-04 – 2024-03-01 · Chronic Heart Failure, Acute Heart Failure, Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT05028140 · EMS
2024-10-08 – 2027-09 · Type II Diabetes
What this study did
NCT04670666 · EMS
2024-11-18 – 2027-06 · Type 2 Diabetes Mellitus
What this study did
NCT05444153 · Novo Nordisk A/S
2022-10-06 – 2025-08-29 · Diabetes Mellitus, Type 2
What this study did
NCT04970108 · EMS
2023-08 – 2025-05 · Hypertension Associated, Type II Diabetes Mellitus
What this study did
NCT02863328 · Novo Nordisk A/S
2016-08-10 – 2018-03-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01422876 · Boehringer Ingelheim
2011-08 – 2013-09 · Diabetes Mellitus, Type 2
What this study did
Phase 2 (2)
Type 2 Diabetes
NCT03462069 · Sanofi
2018-03-12 – 2019-04-18 · Diabetes Mellitus
What this study did
NCT03152552 · Novartis Pharmaceuticals
2017-07-25 – 2018-06-06 · Diabetes Mellitus and Heart Failure
What this study did
Phase 1 (4)
Other / comorbidity
NCT07102719 · Handok Inc.
2025-09-10 – 2025-10-20 · Healthy Volunteers
What this study did
NCT06889350 · Handok Inc.
2025-03-26 – 2025-05-07 · Healthy Volunteers
What this study did
NCT06339788 · Handok Inc.
2024-05-10 – 2024-06-12 · Healthy Volunteers
What this study did
NCT01328184 · Boehringer Ingelheim
2011-04 – 2011-07 · Healthy
What this study did
Phase 4 (4)
Type 2 Diabetes
NCT06642623 · Yonsei University
2024-01-22 – 2030-12-31 · Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases
What this study did
NCT07939750 · Allied Hospital Faisalabad
2026-12-01 – 2028-01-31 · Type 2 Diabetes Mellitus (DM)
What this study did
Other / comorbidity
NCT06410352 · University Medical Center, Kazakhstan
2024-03-01 – 2026-07-31 · Metabolic Syndrome
What this study did
NCT02768220 · Northwell Health
2017-12-01 – 2018-12 · SGLT-2 Inhibitors, Advanced Glycation End Products, Diabetes
What this study did
Early phase / not applicable (1)
Other / comorbidity
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Chronic Kidney Disease
NCT06531824 · Boehringer Ingelheim
2024-08-30 – 2026-12-31 · Kidney Disease, Chronic
What this study did
Heart Failure
NCT06424288 · Boehringer Ingelheim
2024-06-17 – 2028-05-22 · Heart Failure
What this study did
Type 2 Diabetes
NCT07064473 · Boehringer Ingelheim
2025-07-22 – 2029-12-21 · Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Empagliflozin (Jardiance): this drugApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HenagliflozinPhase 3Small moleculeSodium-glucose cotransporter 2 (SGLT2)Reliable signal
NCT04390295: Placebo-adjusted LS mean HbA1c change at Week 24: -0.76% (5 mg) and -0.80% (10 mg) vs placebo, both P < .0001.
NCT03159052: Placebo-adjusted LS mean HbA1c change at Week 24: -0.91% (5 mg) and -0.94% (10 mg) vs placebo, both P < .001.
Janagliflozin (Huiyoujing)Phase 3Small moleculeSGLT2Reliable signal
NCT03811548: Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signalNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPnot yet gradedNo reviewed efficacy summary in this indication
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT06354660: Change in HbA1c from baseline (7.9%) at Week 40: 4 mg -1.7%, 9 mg -2.0%, 12 mg -1.9%, placebo -0.8%; retatrutide met the primary endpoint.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06650007: Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo
NCT06649344: Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met.
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06589765: Primary, HbA1c change from baseline at week 32 vs dapagliflozin 10 mg (non-inferiority margin 0.4%, primary non-inferiority estimand): 30 mg -0.30% (95% CI -0.51 to -0.09), 60 mg -0.22% (95% CI -0.44 to -0.01), 90 mg -0.40% (95% CI -0.62 to -0.19); non-inferiority met for all three doses (all P<0.0001). Superiority (treatment policy estimand): 90 mg -0.25% (95% CI -0.45 to -0.05; one-sided P=0.0067), 60 mg not significant (P=0.0789).
NCT06672172: OUTSTAND-1 phase 3 T2D trial (placebo-controlled, diet-and-exercise inadequately controlled); enrollment (284) matches this listing exactly. Primary endpoint (HbA1c reduction at Week 32 vs placebo, across 30/60/90mg doses) was met: 1.40-1.68% reduction vs 0.06% for placebo.
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DA-2811Phase 2Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Tofogliflozin (Apleway / Deberza)Phase 2Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
OlorigliflozinPhase 1Small moleculeSGLT2Weak signalNo reviewed efficacy summary in this indication

Large race: only the 77 furthest-along competitors are listed; 73 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(88 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Jardiance (Empagliflozin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (18)
November 2026 (2)
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2026-11-30 · NCT05057806 · CT.gov ↗
What to watch
Phase 2/3Empagliflozin in Cardiorenal Syndrome Type 1Recruiting
Est. primary completion 2026-11-30 · NCT06030843 · CT.gov ↗
What to watch
December 2026 (16)
Phase 1Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2026-12 · NCT06554301 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2026-12 · NCT07093476 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2026-12 · NCT07311551 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2026-12-01 · NCT07692256 · CT.gov ↗
What to watch
Phase 2Cirrhosis, Liver FailureRecruiting
Est. primary completion 2026-12-01 · NCT05726032 · CT.gov ↗
What to watch
Phase 1HealthyRecruiting
Est. primary completion 2026-12-11 · NCT07845630 · CT.gov ↗
What to watch
Phase 2Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)Recruiting
Est. primary completion 2026-12-30 · NCT07336797 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2026-12-30 · NCT05786443 · CT.gov ↗
What to watch
Phase 4Lupus Nephritis (LN)Recruiting
Est. primary completion 2026-12-30 · NCT07700940 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2026-12-31 · NCT05392764 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT06989723 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT05164263 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2026-12-31 · NCT06055452 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2026-12-31 · NCT05671991 · CT.gov ↗
What to watch
Phase 4Heart FailureActive not recruiting
Est. primary completion 2026-12-31 · NCT06260059 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesEnrolling by invitation
Est. primary completion 2026-12-31 · NCT06519448 · CT.gov ↗
What to watch
2027 (42)
January 2027 (1)
Phase 3Diabetes Type 1Recruiting
Est. primary completion 2027-01 · NCT06894784 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Heart FailureRecruiting
Est. primary completion 2027-02-01 · NCT07372040 · CT.gov ↗
What to watch
Early phase / not applicableSepsis, Inflammation, SGLT2 Inhibitors, Critically Ill, Organ Dysfunction SyndromeRecruiting
Est. primary completion 2027-02-28 · NCT06473844 · CT.gov ↗
What to watch
March 2027 (4)
Phase 3Cardiogenic ShockRecruiting
Est. primary completion 2027-03-16 · NCT05879276 · CT.gov ↗
What to watch
Phase 2DMD-associated Dilated CardiomyopathyNot yet recruiting
Est. primary completion 2027-03-31 · NCT06643442 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2027-03-31 · NCT06570473 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-03-31 · NCT07442006 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1/2Empagliflozin, Hepatitis B, SteatosisEnrolling by invitation
Est. primary completion 2027-04-01 · NCT07947706 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2027-04-16 · NCT07107945 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2027-04-30 · NCT07038356 · CT.gov ↗
What to watch
Early phase / not applicableHypertension (HTN)Not yet recruiting
Est. primary completion 2027-04-30 · NCT07678151 · CT.gov ↗
What to watch
May 2027 (4)
Phase 4Autosomal Dominant Polycystic KidneyActive not recruiting
Est. primary completion 2027-05 · NCT06391450 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-05-01 · NCT05715814 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2027-05-31 · NCT05138575 · CT.gov ↗
What to watch
Phase 2Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes MellitusRecruiting
Est. primary completion 2027-05-31 · NCT06729996 · CT.gov ↗
What to watch
June 2027 (7)
Phase 2Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2027-06 · NCT07898709 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053306 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053319 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT05960656 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053293 · CT.gov ↗
What to watch
Phase 1/2Obesity, Metabolic SyndromeRecruiting
Est. primary completion 2027-06-30 · NCT05972564 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-06-30 · NCT07292909 · CT.gov ↗
What to watch
July 2027 (4)
Phase 1Pre-Diabetes, Weight, Body, Cardiovascular DiseasesRecruiting
Est. primary completion 2027-07 · NCT06446531 · CT.gov ↗
What to watch
Phase 2Acute Kidney InjuryRecruiting
Est. primary completion 2027-07 · NCT06528405 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-07 · NCT07155694 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-07-31 · NCT06483074 · CT.gov ↗
What to watch
August 2027 (5)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-08 · NCT07365358 · CT.gov ↗
What to watch
Early phase / not applicableBipolar Disorder, Bipolar Depression, Insulin ResistanceRecruiting
Est. primary completion 2027-08 · NCT07472920 · CT.gov ↗
What to watch
Phase 4Atrial Fibrillation, SGLT2 Inhibitor, DC CardioversionRecruiting
Est. primary completion 2027-08-01 · NCT07776054 · CT.gov ↗
What to watch
Phase 2Brugada Syndrome (BrS)Not yet recruiting
Est. primary completion 2027-08-21 · NCT07146880 · CT.gov ↗
What to watch
Early phase / not applicableCardiogenic ShockRecruiting
Est. primary completion 2027-08-31 · NCT07141355 · CT.gov ↗
What to watch
September 2027 (3)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-09 · NCT06613854 · CT.gov ↗
What to watch
Phase 2Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2027-09-30 · NCT07749014 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Supportive Care in CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07883512 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Heart FailureRecruiting
Est. primary completion 2027-11 · NCT06024746 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Rheumatoid Arthritis (RA)Not yet recruiting
Est. primary completion 2027-12 · NCT07864688 · CT.gov ↗
What to watch
Phase 3Congenital Heart DiseaseRecruiting
Est. primary completion 2027-12 · NCT06955260 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-12-01 · NCT06110130 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2027-12-31 · NCT06249945 · CT.gov ↗
What to watch
Phase 4Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver, Empagliflozin, SGLT2 InhibitorsActive not recruiting
Est. primary completion 2027-12-31 · NCT05147090 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-31 · NCT07771010 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2027-12-31 · NCT06249932 · CT.gov ↗
What to watch
2028 (15)
January 2028 (3)
Phase 2Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLDNot yet recruiting
Est. primary completion 2028-01-01 · NCT03867487 · CT.gov ↗
What to watch
Phase 2Non-Alcoholic Fatty Liver DiseaseRecruiting
Est. primary completion 2028-01-01 · NCT06355310 · CT.gov ↗
What to watch
Phase 3CardiotoxicityActive not recruiting
Est. primary completion 2028-01-01 · NCT05271162 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Heart FailureRecruiting
Est. primary completion 2028-02 · NCT07304817 · CT.gov ↗
What to watch
Phase 4Gout and HyperuricemiaRecruiting
Est. primary completion 2028-02-01 · NCT06674109 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Alzheimer DiseaseNot yet recruiting
Est. primary completion 2028-04 · NCT07756294 · CT.gov ↗
What to watch
May 2028 (1)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-05 · NCT07074418 · CT.gov ↗
What to watch
September 2028 (3)
Phase 4Blood Pressure, Endothelial DysfunctionNot yet recruiting
Est. primary completion 2028-09 · NCT07799441 · CT.gov ↗
What to watch
Phase 3PneumoniaRecruiting
Est. primary completion 2028-09-30 · NCT04381936 · CT.gov ↗
What to watch
Phase 3Empgliflozin Cardioprotective EffectNot yet recruiting
Est. primary completion 2028-09-30 · NCT07815808 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2/3Aging, Arterial StiffnessRecruiting
Est. primary completion 2028-10-31 · NCT06506422 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1Kidney StonesRecruiting
Est. primary completion 2028-11-01 · NCT07055282 · CT.gov ↗
What to watch
December 2028 (3)
Phase 4Partial Islet Function, TPIAT, DiabetesRecruiting
Est. primary completion 2028-12-01 · NCT07228195 · CT.gov ↗
What to watch
Phase 2Obesity, Vascular HealthRecruiting
Est. primary completion 2028-12-31 · NCT06745063 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2028-12-31 · NCT06642272 · CT.gov ↗
What to watch
2029 (8)
January 2029 (2)
Phase 1Heart FailureRecruiting
Est. primary completion 2029-01-15 · NCT06507657 · CT.gov ↗
What to watch
Phase 4Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors, CirrhosisRecruiting
Est. primary completion 2029-01-30 · NCT07322237 · CT.gov ↗
What to watch
February 2029 (1)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2029-02-28 · NCT07775846 · CT.gov ↗
What to watch
March 2029 (3)
Phase 2/3Paraffinoma, Granuloma, Foreign-BodyRecruiting
Est. primary completion 2029-03 · NCT07828002 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2029-03-31 · NCT07060417 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesEnrolling by invitation
Est. primary completion 2029-03-31 · NCT07547878 · CT.gov ↗
What to watch
August 2029 (1)
Phase 4Heart Transplant, Cardiovascular Disease, Kidney DiseaseRecruiting
Est. primary completion 2029-08-31 · NCT06625073 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaRecruiting
Est. primary completion 2029-10 · NCT07175051 · CT.gov ↗
What to watch
2030 (4)
March 2030 (1)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2030-03-31 · NCT06013865 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2030-07 · NCT06992440 · CT.gov ↗
What to watch
September 2030 (2)
Phase 3Kidney Stone, Nephrolithiasis, Dietary ExposureRecruiting
Est. primary completion 2030-09 · NCT06653738 · CT.gov ↗
What to watch
Phase 1/2Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 3Coronary Microvascular Dysfunction (CMD)Not yet recruiting
Est. primary completion 2031-05 · NCT07533747 · CT.gov ↗
What to watch

See the full readout calendar ↗